What is the survival rate for myelodysplastic syndrome?

There are many disease problems in modern life, and various diseases have brought great harm to people's health. Among them, myelodysplastic syndrome is the most harmful. The incidence of this disease is also very low, and it is easy to have worsening symptoms, threatening the patient's life safety at any time. Let's take a look at the survival rate of myelodysplastic syndrome. I hope everyone can understand.

(1) The average survival of the very low-risk group is about 141 months;

(2) The average survival of the low-risk group is about 66 months;

(3) The average survival of the intermediate-risk group is about 4 months;

(4) The average survival of the high-risk group is about 26 months;

(5) The average survival time of the extremely high-risk group is approximately 9 months.

treat:

Supportive care

When the patient has obvious anemia or concurrent heart or lung disease, red blood cells can be transfused. RA and RA-S often result in increased iron load due to repeated blood transfusions. In case of bleeding and infection, platelet transfusions and antibiotics may be given. Prophylactic transfusion of granulocytes and platelets has no clear therapeutic effect on patients with MDS.

Vitamin therapy

Some RA-S patients respond to vitamin B6 treatment. 200-500 mg/day intravenous drip can increase reticulocyte count and reduce the amount of blood transfusion.

Adrenal cortex hormone

About 10-15% of MDS patients experience a significant increase in peripheral blood cell count after treatment with corticosteroids, but the side effects of corticosteroid treatment, such as susceptibility to infection and increased blood sugar, cannot be ignored.

Differentiation Inducers

Some cells in the malignant clones of MDS patients still retain differentiation potential, and some drugs can induce tumor cell differentiation. Currently commonly used is 1,25-dihydroxyvitamin D3, 2μg/d orally, for at least 12 weeks. Or use vitamin D3 300,000 to 600,000 units intramuscularly once a day for 8 to 28 weeks. The blood count of some patients improved during medication. This type of drug can cause severe hypercalcemia that is life-threatening, so changes in blood calcium should be closely monitored. 13-cis retinoic acid has an inducing differentiation effect in in vitro culture, but its clinical application is not ideal. In China, all-trans retinoic acid 20 mg is often taken orally three times a day. Low-dose cytarabine has a differentiation-inducing effect on myeloid leukemia and is currently used in MDS, especially RAEB and RAEB-T, with a remission rate of about 30%, 10-20 mg/m2/d subcutaneous injection for 7-21 days. However, the inhibitory effect of low-dose cytarabine on the bone marrow cannot be ignored, and approximately 15% of patient deaths are drug-related.